Effect on Weight Loss of Exenatide Versus Placebo - Study Results

Study Type:	Interventional
Study Design:	Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment
Condition:	Type 2 Diabetes Mellitus
Interventions:	Drug: exenatide Drug: placebo

Participant Flow

Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups

	Description
Group A (Exenatide)	exenatide 5mcg twice daily for 4 weeks, followed by exenatide 10mcg twice daily for 20 weeks
Group B (Placebo)	placebo (volume equivalent to exenatide injection) twice daily for 24 weeks

Participant Flow: Overall Study

	Group A (Exenatide)	Group B (Placebo)
STARTED	96	98
COMPLETED	70	72
NOT COMPLETED	26	26
Adverse Event	4	5
Entry Criteria Not Met	0	1
Loss of Glucose Control	0	1
Lost to Follow-up	10	5
Physician Decision	0	4
Protocol Violation	6	3
Sponsor Decision	0	1
Subject Decision	6	6

Baseline Characteristics

Hide Baseline Characteristics

Reporting Groups

	Description
Group A (Exenatide)	exenatide 5mcg twice daily for 4 weeks, followed by exenatide 10mcg twice daily for 20 weeks
Group B (Placebo)	placebo (volume equivalent to exenatide injection) twice daily for 24 weeks

Baseline Measures

	Group A (Exenatide)	Group B (Placebo)	Total
Number of Participants [units: participants]	96	98	194
Age [units: participants]
<=18 years	0	0	0
Between 18 and 65 years	78	82	160
>=65 years	18	16	34
Age [units: years] Mean ± Standard Deviation	54.52 ± 10.02	55.08 ± 8.97	54.81 ± 9.48
Gender [units: participants]
Female	60	61	121
Male	36	37	73
Baseline Body Weight [units: kg] Mean ± Standard Deviation	94.90 ± 16.52	96.16 ± 16.53	95.53 ± 16.05
Baseline Cholesterol [units: mmol/L] Mean ± Standard Deviation	4.67 ± 1.03	4.68 ± 0.90	4.68 ± 0.96
Baseline Glycosylated Hemoglobin (HbA1c) [units: %] Mean ± Standard Deviation	7.74 ± 0.87	7.51 ± 0.82	7.62 ± 0.85
Baseline High Density Lipoprotein (HDL) Cholesterol [units: mmol/L] Mean ± Standard Deviation	1.18 ± 0.32	1.21 ± 0.31	1.20 ± 0.31
Baseline Homeostatic Model Assessment-Beta Cell (HOMA-B) [units: %] Mean ± Standard Deviation	75.15 ± 81.20	70.72 ± 53.16	72.81 ± 67.65
Baseline Homeostatic Model Assessment-Insulin Sensitivity (HOMA-S) [units: %] Mean ± Standard Deviation	49.72 ± 32.12	62.90 ± 41.07	56.68 ± 37.57
Baseline Low Density Lipoprotein (LDL) Cholesterol [units: mmol/L] Mean ± Standard Deviation	2.74 ± 0.88	2.78 ± 0.82	2.76 ± 0.85
Baseline Triglycerides [units: mmol/L] Mean ± Standard Deviation	2.15 ± 0.94	2.13 ± 1.00	2.14 ± 0.97
Baseline Waist Circumference [units: cm] Mean ± Standard Deviation	109.64 ± 11.12	108.85 ± 12.10	109.24 ± 11.60

Outcome Measures

Show All Outcome Measures

1. Primary:

Change in Body Weight [ 24 weeks ]

Show Outcome Measure 1

2. Secondary:

Change in Glycosylated Hemoglobin (HbA1c) [ 24 weeks ]

Show Outcome Measure 2

3. Secondary:

Change in 6-point Self Monitored Blood Glucose (SMBG) Profile. [ 24 weeks ]

Show Outcome Measure 3

4. Secondary:

Change in Waist Circumference. [ 24 weeks ]

Show Outcome Measure 4

5. Secondary:

Change in Homeostatic Model Assessment-Beta Cell (HOMA-B) [ 24 weeks ]

Show Outcome Measure 5

6. Secondary:

Change in Homeostatic Model Assessment-Insulin Sensitivity (HOMA-S) [ 24 weeks ]

Show Outcome Measure 6

7. Secondary:

Change in High Density Lipoprotein (HDL) Cholesterol [ 24 weeks ]

Show Outcome Measure 7

8. Secondary:

Change in Low Density Lipoprotein (LDL) Cholesterol [ 24 weeks ]

Show Outcome Measure 8

9. Secondary:

Change in Total Cholesterol [ 24 weeks ]

Show Outcome Measure 9

10. Secondary:

Change in Triglycerides [ 24 weeks ]

Show Outcome Measure 10

11. Secondary:

Incidence of Hypoglycemic Events [ 24 weeks ]

Show Outcome Measure 11

12. Secondary:

Rate of Hypoglycemic Events [ 24 weeks ]

Show Outcome Measure 12

Serious Adverse Events

Show Serious Adverse Events

Other Adverse Events

Hide Other Adverse Events

Time Frame	No text entered.
Additional Description	No text entered.

Frequency Threshold

Threshold above which other adverse events are reported	≥ 5%

Reporting Groups

	Description
Group A (Exenatide)	exenatide 5mcg twice daily for 4 weeks, followed by exenatide 10mcg twice daily for 20 weeks
Group B (Placebo)	placebo (volume equivalent to exenatide injection) twice daily for 24 weeks

Other Adverse Events

	Group A (Exenatide)	Group B (Placebo)
Total, other (not including serious) adverse events
# participants affected	87	82
Gastrointestinal disorders
Nausea ^†^A # participants affected / at risk	43/96 (44.79%)	19/98 (19.39%)
Diarrhea ^†^A # participants affected / at risk	18/96 (18.75%)	21/98 (21.43%)
Vomiting ^†^A # participants affected / at risk	21/96 (21.88%)	9/98 (9.18%)
Constipation ^†^A # participants affected / at risk	9/96 (9.38%)	10/98 (10.20%)
Dysgeusia ^†^A # participants affected / at risk	5/96 (5.21%)	1/98 (1.02%)
General disorders
Injection site bruising ^†^A # participants affected / at risk	5/96 (5.21%)	14/98 (14.29%)
Injection site pruritus ^†^A # participants affected / at risk	6/96 (6.25%)	0/98 (0.00%)
Injection site erythema ^†^A # participants affected / at risk	5/96 (5.21%)	0/98 (0.00%)
Infections and infestations
Upper respiratory tract infection ^†^A # participants affected / at risk	17/96 (17.71%)	17/98 (17.35%)
Nasopharyngitis ^†^A # participants affected / at risk	11/96 (11.46%)	6/98 (6.12%)
Urinary tract infection ^†^A # participants affected / at risk	3/96 (3.13%)	7/98 (7.14%)
Injury, poisoning and procedural complications
Contusion ^†^A # participants affected / at risk	6/96 (6.25%)	4/98 (4.08%)
Metabolism and nutrition disorders
Decreased appetite ^†^A # participants affected / at risk	6/96 (6.25%)	6/98 (6.12%)
Musculoskeletal and connective tissue disorders
Back pain ^†^A # participants affected / at risk	4/96 (4.17%)	8/98 (8.16%)
Pain in extremity ^†^A # participants affected / at risk	7/96 (7.29%)	5/98 (5.10%)
Myalgia ^†^A # participants affected / at risk	5/96 (5.21%)	2/98 (2.04%)
Musculoskeletal pain ^†^A # participants affected / at risk	1/96 (1.04%)	5/98 (5.10%)
Nervous system disorders
Headache ^†^A # participants affected / at risk	11/96 (11.46%)	9/98 (9.18%)
Dizziness ^†^A # participants affected / at risk	5/96 (5.21%)	5/98 (5.10%)
Respiratory, thoracic and mediastinal disorders
Cough ^†^A # participants affected / at risk	5/96 (5.21%)	6/98 (6.12%)
Nasal congestion ^†^A # participants affected / at risk	5/96 (5.21%)	0/98 (0.00%)

^†	Indicates events were collected by systematic assessment.
^A	Term from vocabulary, MedDRA 11.0

More Information

Hide More Information

Certain Agreements:

Principal Investigators are NOT employed by the organization sponsoring the study.

There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

The agreement is:

	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed.

Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

Results Point of Contact:

Name/Title: Chief Medical Officer
Organization: Eli Lilly and Company
phone: 1-800-LILLYRX
e-mail: clinicaltrials@amylin.com

No publications provided

Responsible Party:	Eli Lilly and Company ( James Malone, MD, Study Director )
Study ID Numbers:	H8O-US-GWBM
Study First Received:	September 11, 2006
Results First Received:	February 25, 2009
Last Updated:	July 30, 2009
ClinicalTrials.gov Identifier:	NCT00375492 History of Changes
Health Authority:	United States: Food and Drug Administration